Passer à la navigation principale Passer à la recherche Passer au contenu principal

Sicca induced by immune checkpoint inhibitors

  • Rakiba Belkhir
  • , Marjolaine Gosset
  • , Antoine Rousseau
  • , Samuel Bitoun
  • , Thierry Lazure
  • , Xavier Mariette
  • , Gaetane Nocturne
  • Assistance Publique-Hôpitaux de Paris
  • INSERM U869
  • Charles Foix Hospital
  • Université Paris-Saclay
  • South Paris University

Résultats de recherche: Contribution à un journal › Bref sondage › Revue par des pairs

1 Citation (Scopus)

Résumé

Background Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but are associated with immune-related adverse events (irAEs), including sicca syndrome. This condition, characterized by ocular and oral dryness, is under-recognized yet significantly impacts patients' quality of life. Objectives This review aims to highlight the prevalence, clinical features, and management strategies for ICI-induced sicca syndrome, emphasizing its distinction from Sjögren disease (SjD) and the importance of early detection and treatment. Key points Sicca induced by immune checkpoint inhibitors (ICI) is under-estimated but might affect 5 to 24 % of the patients treated by ICI. The pathophysiology of ICI-induced sicca is different from SjD, with infiltration of salivary glands mainly by T lymphocytes. Management of sicca induced by ICI consists of a graded approach, including symptomatic treatment and corticosteroids. Future directions Future research on ICI-induced sicca syndrome should focus on prospective studies to accurately determine its frequency and validate screening tools for early diagnosis. Assessing the benefits of early immunomodulatory treatments and exploring the long-term outcome of the condition are also essential. Understanding the immunological mechanisms and risk factors will be crucial to improve the management. Collaboration among specialists is mandatory to develop comprehensive management guidelines and improving patient condition.

langue originaleAnglais
Numéro d'article104331
journalPresse Medicale
Volume55
Numéro de publication2
Les DOIs
étatPublié - 1 juin 2026
Modification externeOui

SDG des Nations Unies

Ce résultat contribue à ou aux Objectifs de développement durable suivants

  1. SDG 3 - Bonne santé et bien-être
    SDG 3 Bonne santé et bien-être

Empreinte digitale

Examiner les sujets de recherche de « Sicca induced by immune checkpoint inhibitors ». Ensemble, ils forment une empreinte digitale unique.

Contient cette citation